Arcadia Biosciences, Inc. (RKDA) Stock Price & Analysis
Arcadia Biosciences, Inc. (RKDA) rose 4.05% to USD 0.64 as of July 25, 2026 at 06:08 UTC, according to Nexqual real-time market data.
RKDA last closed at USD 0.62; the session ranged USD 0.62–0.65 on volume of 5,315 shares. Market capitalization is $1.40M, with a 52-week range of USD 0.59–6.71 (NCM). Source: Nexqual, July 25, 2026 at 06:08 UTC.
Key Statistics (as of July 25, 2026 at 06:08 UTC)
| Price | USD 0.64 |
|---|---|
| Change | ▲ 4.05% (up) |
| Previous Close | USD 0.62 |
| Open | USD 0.63 |
| Day Range | USD 0.62 – 0.65 |
| 52-Week Range | USD 0.59 – 6.71 |
| Volume | 5,315 shares |
| Market Cap | $1.40M |
| Exchange | NCM |
Technical Analysis (RKDA)
Nexqual's technical model rates RKDA "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:08 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.91 (neutral) |
| vs SMA50 | Below (USD 0.82) |
| MACD | -0.05 (negative) |
Analyst Ratings (RKDA)
Wall Street analysts rate RKDA "None", per Nexqual as of July 25, 2026 at 06:08 UTC.
| Consensus Rating | None |
|---|
Earnings (RKDA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD 0.62 vs est -0.54 ▲ beat |
| 2025-06-30 | USD -3.26 vs est -0.79 ▼ miss |
| 2025-03-31 | USD 1.9 vs est -0.98 ▲ beat |
| 2024-12-31 | USD -2.99 vs est -0.89 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:08 UTC.
Financials & Fundamentals (RKDA)
| Total Revenue | $4.76M |
|---|---|
| Revenue Growth (YoY) | -8.30% |
| Gross Margin | +34.32% |
| Operating Margin | -70.82% |
| Profit Margin | -195.94% |
| ROE | -158.15% |
| Current Ratio | 3.79 |
| Total Cash | $3.72M |
| Total Debt | $0 |
| Free Cash Flow | $1.29M |
Source: Nexqual, July 25, 2026 at 06:08 UTC.
Financial Health Score (RKDA)
Nexqual rates Arcadia Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:08 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $4M cash, no debt |
| Cash Flow | Strong — FCF $1M, 26% margin |
| Efficiency | Critical — ROE -158%, ROA -32.8% |
Ownership (RKDA)
| Insider Ownership | +0.16% |
|---|---|
| Institutional Ownership | +16.01% |
| Shares Outstanding | 2.18M |
| Float | 1.79M |
| Short % of Float | +1.07% |
Source: Nexqual, July 25, 2026 at 06:08 UTC.
Leadership (RKDA)
Arcadia Biosciences, Inc. is led by Thomas J. Schaefer C.F.A. (age 49), CEO, Interim CFO, Principal Accounting Officer, President, Corporate Secretary & Director, per Nexqual as of July 25, 2026 at 06:08 UTC.
| CEO, Interim CFO, Principal Accounting Officer, President, Corporate Secretary & Director | Thomas J. Schaefer C.F.A. (age 49) |
|---|
Major Backers & Investors (RKDA)
Notable institutional backers of Arcadia Biosciences, Inc. include Armistice Capital, LLC, Sabby Management, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 06:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 7.31% |
| Sabby Management, LLC | 5.25% |
| Fidelity | 1.43% |
| Susquehanna International Group, LLP | 0.58% |
| Tower Research Capital LLC (TRC) | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.45% |
| Vanguard Group | 1.08% |
| State Street | 0.56% |
Source: Nexqual, July 25, 2026 at 06:08 UTC.
From Arcadia Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Partnerships
- On December 24, 2025, the Company received a notice from Roosevelt indicating that it was terminating the Exchange Agreement with immediate effect pursuant to the Termination Provision, as the closing of the Exchange had not occurred by the Termination Date specified in the Amendment.
- On March 28, 2025, Arcadia entered into an agreement with Bioceres Crop Solutions Corp. ("BIOX") pursuant to which BIOX agreed to transfer to the Company all rights and materials relating to certain soy traits that were included in licenses granted by the Company to BIOX in the November 2020 sale of Verdeca.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BPTH | Bio-Path Holdings, Inc. | USD 0.04 | ▲ 0% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
| TENX | Tenax Therapeutics, Inc. | USD 14.53 | ▼ 1.76% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:08 UTC. This page is informational and not investment advice.